Total population N=708 | Patients with radiographic follow-up N=432 | Patients without radiographic follow-up N=262 | |
Age (years) (mean±SD) | 33.74 (8.63) | 34.27 (8.66) | 32.90 (8.54) |
Gender (female, %) | 381 (53.8%) | 230 (53.24%) | 151 (54.7%) |
Menopausal status (n, %) | 17 (4.46%) | 10 (4.35%) | 7 (2.6%) |
BMI (mean±SD) | 23.99 (4.64) | 23.94 (4.13) | 23.82 (3.9) |
CRP (mean±SD) | 7.90 (13.54) | 7.88 (13.40) | 7.93 (13.7) |
BASDAI (mean±SD) | 44.70 (20.00) | 43.53 (19.90) | 46.53 (20.0) |
BASFI (mean±SD) | 30.45 (22.75) | 29.46 (22.59) | 31.99 (22.96) |
Prevalence of IBD | 35 (4.94%) | 24 (5.56%) | 11 (4.2%) |
Disease duration (years) | 1.51 (0.87) | 1.49 (0.89) | 1.55 (0.84) |
Past use of corticosteroids (n, %) | 93 (13.13%) | 55 (12.73%) | 38 (14.5%) |
Score NSAIDs (mean±SD) | 44.72 (40.46) | 46.05 (39.64%) | 42.63 (41.70) |
Use of at least one anti-TNF treatment during the 5 years (n, %) | 258 (36.44%) | 197 (45.60%) | 61 (23.30%) |
Lumbar spine BMD l (mean±SD) | 1.07 (0.16) | 1.07 (0.17) | 1.07 (0.15) |
Hip BMD (mean±SD) | 0.99 (0.14) | 1.00 (0.14) | 0.91 (0.14) |
Femoral neck BMD (mean±SD) | 0.92 (0.15) | 0.98 (0.13) | 0.91 (0.14) |
Presence of Z score < or =−2 at least one site (n, %) | 46 (6.49%) | 34 (7.87%) | 12 (4.58%) |
mSASSS baseline (mean±SD) | 0.49 (1.83) | 0.50 (1.48) | 0.49 (2.29) |
SIJ SPARCC score baseline (mean±SD) | 4.87 (9.04) | 5.43 (9.50) | 3.91 (8.15) |
HLA B27 antigen (n, %) | 410 (57.99%) | 268 (62.04%) | 142 (54.2%) |
Current smoking (n, %) | 257 (36.35%) | 158 (36.57%) | 99 (37.78%) |
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMD, bone mineral density; BMI, Body Mass Index; CRP, C reactive protein; IBD, inflammatory bowel disease; mSASSS, modified Stokes Ankylosing Spondylitis Spinal Score; NSAID, non-steroidal anti-inflammatory drug; SIJ, sacroiliac joint; SPARCC, SpondyloArthritis Research Consortium of Canada; TNF, tumour necrosis factor.